​ ​ ​ ​ Homepage | Ebv+ptld
Aller au contenu Aller au menu

Connect the dots in EBV+ PTLD

Following solid organ or haematopoietic cell transplantation, proliferation of Epstein–Barr virus (EBV)-infected B cells can lead to potentially life-threatening post-transplant lymphoproliferative disorders (PTLD)

Uncover key aspects of PTLD and explore strategies for optimising patient care

Essential content

  • Disease Pathogenesis

    EBV+ PTLD arises from immunosuppression after solid organ or haematopoietic cell transplantation driven by impaired T-cell function and surveillance.

    Click here to learn more
  • Clinical Presentation & Diagnosis

    Clinical Presentation and Diagnosis

    Risk factors for EBV+ PTLD vary after solid organ or haematopoietic cell transplantation. These may include age, duration of immunosuppression, and degree of T-cell impairment.

    Click here to learn more
  • EBV Patient Mangement & Treatment outcomes

    Patient management & treatment outcomes

    There are a range of therapy options for EBV+ PTLD, however, some patients experience failure of initial therapy with limited alternative treatment options

    Click here to learn more
  • Clinical Trials

    Clinical Trials

    Discover active research studies, including studies exploring treatments for patients with newly diagnosed or R/R EBV+ PTLD Click here to learn more

    Click here to learn more
EBV patient website

Patient website

A dedicated website for patients is also available. Feel free to share it with your patients if they wish to better understand their condition and access numerous resources on Post-Transplant Lymphoproliferative Disease.

Go to patient website